Ipamorelin
low riskAlso: NNC 26-0161 · Ipamorelin acetate
Ipamorelin is a selective GH secretagogue notable for minimal cortisol/prolactin elevation — making it the 'cleanest' GHRP. Human pharmacokinetic data exists. Most commonly combined with CJC-1295 for synergistic GH release.
Reported Benefits
Selective GH stimulation
Dose-dependent GH release without significant cortisol/prolactin spikes — confirmed in human and animal studies.
Body composition
GH-mediated effects expected; limited direct human body composition data.
Mechanism of Action
Selective GHS-R1a agonist. Stimulates GH release with high selectivity — minimal ACTH, cortisol, or prolactin effects compared to other GHRPs.
Key Clinical Studies
Raun et al. (1998)
Controlled · Animal (dog/rat)
Selective GH release without cortisol/prolactin elevation
The Selectivity Advantage
Ipamorelin’s defining characteristic is selectivity. Unlike GHRP-2 and GHRP-6, it does not meaningfully elevate cortisol or prolactin. This makes it the preferred first-line secretagogue in GH optimization protocols.
Standard Stack
Ipamorelin + CJC-1295 (no DAC): different receptors (ghrelin vs. GHRH), synergistic effect, pulsatile pattern mimicking natural GH secretion.
Regulatory Status
RestrictedSafety Profile
Side Effects
- •Mild flushing
- •Headache
- •Lightheadedness
- •Water retention (high doses)
Contraindications
- •Active malignancy
- •Pregnancy
Drug Interactions
- •Somatostatin analogs
- •Glucocorticoids
Primary Uses
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Ipamorelin?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →